TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04330365

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Whole Health Team (WHT) Intervention Arm, Primary Care Group Education (PC-GE) Intervention Arm, Usual Primary Care (UPC) Arm
Description: Participants will be randomly assigned at the individual level to either WHT, PC-GE or Usual Primary Care, stratified by site, sex, and use of prescribed opioids for chronic pain. The follow-up period for the three arms will be 12 months. The primary outcome is change in pain interference. Secondary outcomes include change in pain intensity, functioning, quality of life, changes in use of pain medications, including opioids (if applicable) and changes in nonpharmacological pain self-management activities. After the baseline assessment, masked telephone assessments will be administered to participants at 3, 6, 9, and 12 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Whole Health Team (WHT) Intervention Arm, Primary Care Group Education (PC-GE) Intervention Arm, Usual Primary Care (UPC) Arm
Description: Participants will be randomly assigned at the individual level to either WHT, PC-GE or Usual Primary Care, stratified by site, sex, and use of prescribed opioids for chronic pain. The follow-up period for the three arms will be 12 months. The primary outcome is change in pain interference. Secondary outcomes include change in pain intensity, functioning, quality of life, changes in use of pain medications, including opioids (if applicable) and changes in nonpharmacological pain self-management activities. After the baseline assessment, masked telephone assessments will be administered to participants at 3, 6, 9, and 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Whole Health Team (WHT) Intervention Arm, Primary Care Group Education (PC-GE) Intervention Arm, Usual Primary Care (UPC) Arm
Description: Participants will be randomly assigned at the individual level to either WHT, PC-GE or Usual Primary Care, stratified by site, sex, and use of prescribed opioids for chronic pain. The follow-up period for the three arms will be 12 months. The primary outcome is change in pain interference. Secondary outcomes include change in pain intensity, functioning, quality of life, changes in use of pain medications, including opioids (if applicable) and changes in nonpharmacological pain self-management activities. After the baseline assessment, masked telephone assessments will be administered to participants at 3, 6, 9, and 12 months.
Study: NCT01905254

Intervention type: DEVICE
Group type: OTHER
Intervention: Transient elastography (TE)
Description: TE and minilaparoscopic guided liver biopsy were performed by physicians blinded to the results the other within a period of less than 3 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Liver biopsy
Description: Minilaparoscopic guided liver biopsy was performed within a period of 3 months of Transient Elastography
Study: NCT00142922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaking Down Barriers
Description: completed

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breaking Down Barriers
Description: completed
Study: NCT01679457

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT-Focused ERP
Study: NCT00142922

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breaking Down Barriers
Description: completed
Study: NCT01268202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin 40mg/day during 12 months
Study: NCT00737880

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Organ perfusion during pancreas procurement
Description: Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Organ perfusion during pancreas procurement
Description: Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement
Study: NCT02995850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS+HIPEC
Description: 1. Ib~   * Dose-escalation of intraperitoneal paclitaxel will follow a modified 3 + 3 dose escalation procedure.~2. II~   ① CRS If PCI \<12, CRS will be performed by gastrectomy with D2-lymphadenectomy and resection of any involved adjacent structures.~   If PCI≥12, instead of CRS, 3 times of IP paclitaxel +cisplatin and oral S-1 chemotherapy every 3 weeks, and then PCI \<12, CRS will be done.~   ② Extensiveintraperitoneal lavage Peritoneal lavage after CRS will be done with 10 L before HIPEC.~   ③ HIPEC Following surgery HIPEC will be performed using CDDP (60 mg/m2) and PTX (P2RD mg/m2). IP chemotherapy will be performed.~   ④ Post-operative intraperitoneal chemotherapy Postoperative chemotherapy will be done 8 cycles of IP paclitaxel+ cisplatin and oral S-1 after 4 weeks.
Study: NCT03715712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized blood pressure management
Description: Standardized blood pressure management of a mean blood pressure \> 65mmHg and a systolic blood pressure of \< 160mmHg using norepinephrine continuous infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized blood pressure management
Description: Individualized blood pressure management of 20% within the preoperative ward blood pressure using norepinephrine continuous infusion
Study: NCT01771822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 5% topical gel
Description: 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical gel vehicle
Description: 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium lauryl sulfate 0.2%
Description: 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium chloride solution 0.9% (saline)
Description: 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
Study: NCT02478125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Burixafor Hydrobromide
Description: Investigators will determine the kinetics of PCa cell release into the blood with four daily dosages of Burixafor hydrobromide alone or in combination with G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV. The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
Study: NCT02139358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The Phase I trial will start at the recommended phase II dose (RP2D) for gemcitabine but will have a de-escalation dose levels in the event that an unacceptable toxicity requires dose reduction. Dose level 0 = gemcitabine (1200 mg/m2) IV D1,8 q21 days; Dose level -1 = gemcitabine (1000 mg/m\^2) IV D1,8 q21 days; Dose level -2 = gemcitabine (850 mg/m\^2) IV D1,8 q21 days. The RP2D will be the dose level where 0-1 dose limiting toxicities (DLTs) in six patients occur.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be given using an 8 mg/kg loading dose on cycle one, day one (C1D1), followed by 6 mg/kg IV on subsequent cycles every (q) 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be given using an 840 mg IV loading dose on C1D1, followed by 420 mg IV on subsequent cycles q 21 days.
Study: NCT04456335

Intervention type: GENETIC
Intervention: Collection of supragingival plaque from caries free children
Description: Supragingival plaque samples were collected from posterior molar teeth

Intervention type: GENETIC
Intervention: Collection of supragingival plaque from caries free children
Description: Supragingival plaque samples were collected from posterior molar teeth
Study: NCT02965755

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment recommendation
Description: Depending on the results from the participant's archival tissue, a panel of Johns Hopkins investigators will meet to interpret the molecular and genetic profiling results in order to identify any actionable mutations to provide a personalized treatment recommendation for the patient.
Study: NCT05767775

Intervention type: OTHER
Intervention: Assessment of synovial- and adipose tissue-derived inflammatory biomarkers
Description: Parafﬁn-embedded synovial tissue (ST) specimens will be stained for H\&E and other sections will be stained for CD68, CD21, CD20, CD3, CD31 and Masson Trichrome Goldner with light green to assess the microanatomical organization of resident synovial inflammatory cells. Some synovial samples will be used for tissue resident macrophages subpopulations analysis using FACS gated on their expression of the CD64+/CD11b+/MHC-ClassII+/CD206+/-/Lineage-.~Each RA patient reaching a stable clinical (DAS\<1.6 for at least two different evaluations 6 months apart) and imaging (PDUS negative signal) remission under Tofacitinib treatment will undergo synovial biopsy and each synovial tissue sample will be processed as above.~Plasma levels of adipokines will be tested through ELISA method at baseline, 3, 6 and 12 months of follow-up in all patients.

Intervention type: OTHER
Intervention: Assessment of synovial- and adipose tissue-derived inflammatory biomarkers
Description: Parafﬁn-embedded synovial tissue (ST) specimens will be stained for H\&E and other sections will be stained for CD68, CD21, CD20, CD3, CD31 and Masson Trichrome Goldner with light green to assess the microanatomical organization of resident synovial inflammatory cells. Some synovial samples will be used for tissue resident macrophages subpopulations analysis using FACS gated on their expression of the CD64+/CD11b+/MHC-ClassII+/CD206+/-/Lineage-.~Each RA patient reaching a stable clinical (DAS\<1.6 for at least two different evaluations 6 months apart) and imaging (PDUS negative signal) remission under Tofacitinib treatment will undergo synovial biopsy and each synovial tissue sample will be processed as above.~Plasma levels of adipokines will be tested through ELISA method at baseline, 3, 6 and 12 months of follow-up in all patients.
Study: NCT01978080

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesia HomeView

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesia HomeView
Study: NCT01602081

Intervention type: DEVICE
Intervention: reinforce soft tissue
Description: reinforce soft tissue
Study: NCT01686581

Intervention type: DRUG
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) administered according to physician prescription.
Study: NCT03758014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorogenic acid for Injection
Description: Chlorogenic acid (CHA) is a class 1 innovative small molecular natural drug, developed by Sichuan Jiuzhang Biological Science and Technology Co., Ltd. The mechanism of broad-spectrum antitumor activity is immunoregulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy. It is closely related to semustine and is in the same family as streptozotocin. It is a highly lipid-soluble drug, thus it crosses the blood-brain barrier. This property makes it ideal for treating brain tumors, which is its primary use.
Study: NCT05029024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30-minute mindful breathing
Description: The four exercises included identifying the in-and out-breath, following the entire length of the breath, bringing the mind back to the body and relaxing the whole body. Each exercise lasted 7.5 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: standard care alone
Study: NCT00737412

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic: Bio-K+ CL1285
Description: The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules devoid of microorganisms
Study: NCT02306122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist calls patient unless physician cancels call

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient nonadherence information sent to physician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient nonadherence information sent to physician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient nonadherence information sent to physician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient nonadherence information sent to physician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient nonadherence information sent to physician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist calls patient if physician requests call

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doctor receives information and may be allowed certain actions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doctor receives information and may be allowed certain actions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doctor receives information and may be allowed certain actions
Study: NCT03387241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/ Formoterol
Description: See above

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/ salmeterol
Description: See above
Study: NCT02970253

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capsular resection
Description: Capsular resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capsular retention
Description: Capsular retention
Study: NCT04180735

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation
Study: NCT02813746

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fitness program

Intervention type: BEHAVIORAL
Intervention: Stop smoking

Intervention type: PROCEDURE
Intervention: Endometrial fluid collection

Intervention type: PROCEDURE
Intervention: Endometrial fluid collection
Study: NCT02010801

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irreversible electroporation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nanoknife AngioDynamics US Ltd
Study: NCT04535622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A structured exercise
Description: Exercise training will be conducted by a physical therapist which will take about 10 to 15 minutes. Patient education will include how to keep face down in various postures, and how to actively exercise the related muscles and joints while maintaining face-down posture through video clip and brochure. Patients will go through three times of self-exercise sessions everyday according to the training provided to the patients. Active exercise for the FDP patients will include exercise in a hands and knees position, limb exercise in an FDP, and exercise in a standing position. The exercises were performed within the range of individual muscle strength and fitness.
Study: NCT00116402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone and salmeterol
Description: 1. will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID~2. will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone and salmeterol
Description: 1. will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID~2. will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID.
Study: NCT03545347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone Decanoate
Description: Injections every 3 weeks, last injection at week 12. Women 50 mg, men with total testosterone ≥ 11 nmol/l will receive 100 mg, and men with total testosterone \< 11 nmol/l will receive a dose of 200 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-rich nutritional supplement
Description: The protein-rich nutritional supplement is a liquid containing 18 g milk-based protein pr bottle. Patients will receive a minimum of 1.35 g/kg bodyweight/day); which means that most patients will receive 2 bottles per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein-rich nutritional supplement
Description: The protein-rich nutritional supplement is a liquid containing 18 g milk-based protein pr bottle. Patients will receive a minimum of 1.35 g/kg bodyweight/day); which means that most patients will receive 2 bottles per day for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: The physical therapy intervention will include progressive strength training initiated daily on weekdays during hospitalization and continued twice per week in the outpatient rehabilitation program in the municipality (treatment as usual but with strength training as an obligatory component) for a total intervention period of 12 weeks from time of inclusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical therapy
Description: The physical therapy intervention will include progressive strength training initiated daily on weekdays during hospitalization and continued twice per week in the outpatient rehabilitation program in the municipality (treatment as usual but with strength training as an obligatory component) for a total intervention period of 12 weeks from time of inclusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/ml Injection
Description: Placebo injection of 1 ml Sodium Chloride
Study: NCT02520648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuro-lymphatic treatment
Description: The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement.
Study: NCT02349919

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 4 weeks
Study: NCT03986788

Intervention type: OTHER
Group type: OTHER
Intervention: Weightlessness
Description: Volunteers will be studied during parabolic flight. Cerebral blood flow will be measured in different part of the brain during weightlessness ans compared to 1g and hypergravity measurements.
Study: NCT02056457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsible Fatherhood or Healthy Marriage Program
Description: RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other services in the community
Description: RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
Study: NCT00744549

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E
Description: Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E
Description: Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Twice a day with meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Twice a day with meals.
Study: NCT02520648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Articulatory spinal manual therapy
Description: Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Articulatory costal Manual therapy
Description: The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier.
Study: NCT03696797

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Donation
Description: Participants in the TREATMENT GROUP will have a Unit of blood (two cups, the same amount you would donate at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure blood count to be sure participants are not anemic, and blood pressure to be sure there is no dehydration. During or after donation, participants will be given a sports drink to replace the fluid loss. Participants in the CONTROL GROUP will not donate blood, but will have a needle inserted into a vein in your arm. Neither group will not know to which they have been assigned, all will have a sleep mask (like a blindfold, covering the eyes, held on with an elastic band) placed so they will not know whether blood was actually removed.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Blood Donation
Description: Participants will have a needle inserted their arm, however, no blood will be drawn.